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Abstract A rapid and easy method to screen for aberrant
cDNA would be a very useful diagnostic tool in genetics
since a fraction of the DNA variants found affect RNA
splicing. The currently used RT-PCR methods require new
primer combinations to study each variant that might affect
splicing. Since MLPA is routinely used to detect large
genomic deletions and successfully detected exon skipping
events in Duchenne muscular dystrophy in cDNA, we per-
formed a pilot study to evaluate its value for BRCA1 cDNA.
The effect of puromycin, DNase I and two different DNA
cleaning protocols were tested in the RNA analysis of lym-
phocyte cultures. We used two samples from unrelated
familieswithtwodifferentBRCA1exondeletionevents,two
healthy unrelated controls and six samples from hereditary
breast/ovarian cancer syndrome (HBOC) patients without
BRCA1/2 mutations. Using RNA treated with DNase I and
cleaned in a column system from puromycin-treated frac-
tions, we were able to identify the two BRCA1 deletions.
Additional HBOC patients did not show additional splice
events. However, we were not able to get reproducible
results. Therefore, the cDNA-MLPA technique using kit
BRCA1P002isinourhandscurrentlynotreliableenoughfor
routine RNA analysis and needs further optimization.
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Introduction
Genetic screening of the BRCA1 and BRCA2 genes is offered
tofamilieswithhighriskofbreastandovariancancer.Besides
clear pathogenic mutations and polymorphisms, unclassiﬁed
variants (UVs) of unclear clinical relevance are found. Some
of these UVs may result in aberrant splicing, by affecting the
d o n o ro ra c c e p t o rs p l i c es i t e s ,o re x o n i cs p l i c es i t ee n h a n c e r
(ESE) sites [1] as predicted in silico. Additionally, deep
intronicvariants,whicharenormallyignored,mayalsoaffect
splicing.Oneexampleofadeepintronicpathogenicvariantis
the variant CDKN2A IVS2-105A[G, which causes retention
of intronic sequence [2]. Another example is the mutation
c.903?409T[C in the MTRR (methionine synthase reduc-
tase)gene,whichactivatesapseudoexon,causingaframeshift
insertion that leads to a premature stop codon [3]. Experi-
mental proof is needed to conﬁrm the predicted changes in
RNA splicing. The experiments are usually performed using
RT-PCR, for which a set of speciﬁc primers targeted to the
relevantcDNAregionisneededforeverynewvariant[4–7].It
is noteworthy that exon skipping is the most common alter-
nativespliceevent[8].AfterthereportofKesarietal.[9],who
were able to detect skipping events on cDNA from the
Duchenne muscular dystrophy (DMD) gene using the
respective genomic multiplex ligation probe ampliﬁcation
(MLPA) kit, we sought to evaluate the use of a commercially
available BRCA1 MLPA kit [10] for the detection of exon
skippingincDNAinsteadofgenomicDNA.BRCA1MLPAis
a multiplex assay based on the hybridization of a large set of
primersthroughoutthe entirecodingpartoftheBRCA1gene.
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exon skipping events in cDNA in the presence of a variant
affecting splicing, without the need to design a speciﬁc RT-
PCR assay for each variant. Although these are likely rare
events,usingarapidandrelativelycheapassaytoassessthem
would be valuable in a diagnostic setting to rule out their
presence.
For this pilot study, samples with BRCA1 exon 13
skipping (c.4242-1643del3835) or exon 22 skipping
(c.5333-36del510) [11] were selected. The study also
included samples from two unrelated healthy controls and
six samples from patients belonging to high risk families
for which no BRCA1 or BRCA2 mutation was identiﬁed in
the standard diagnostic screening. Here we show that the
MLPA method was able to detect the skipping events, but
it was not reproducible enough for use in clinical testing
despite the optimization attempts which are here described.
Materials and methods
Cell culture
White blood cells were isolated and cultured in complete
medium consisting of: RPMI 1640 supplemented with
L-glutamine (Gibco) and 12.5% FCS with additional
supplements and antibiotics. Lymphocyte growth was
stimulated with 50 lL/mL PHA (Gibco) and 10 U/mL of
IL-2 (Roche). At day 7, 4–6 h before harvesting the cells,
cultures were treated with 200 lg/mL of puromycin
(Sigma), to enrich for transcripts containing premature stop
codons by the inhibition of NMD [12].
RNA isolation, cDNA synthesis and MLPA reaction
TotalRNAwasisolatedusingTRIzol(Invitrogen)orTRIpure
(Roche)reagent.RNAsamplesusedwereeithernotsubjected
toDNaseItreatmentortreatedwithDNA-freekit(AMBION)
or with DNase I treatment followed by puriﬁcation in the
column system RNeasy MinElute Kit (Qiagen). First-strand
cDNA was obtained with Reverse Transcriptase M-MUL
(Finnzymes) using random hexamers (Invitrogen) following
the manufacturers’ instructions. The cDNA was ampliﬁed
with the SALSA MLPA P002 probe mix (MRC-Holland)
according to the manufacturer’s protocol. Fragment analysis
wasperformedbycapillaryelectrophoresisinanABIPRISM
3730 automatic sequencer (Applied Biosystems).
Data analysis
The size calling and the peak areas were assessed using the
Genemarker software (Softgenetics) and exported to a
Fig. 1 MLPA results obtained
using puromycin-treated and
non-treated samples as
indicated. Healthy controls
without BRCA1 mutations are
indicated as WT, whereas P1
and P2 are positive controls
with exon 13 and exon 22
deletion events, respectively
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in three independent
experiments for puromycin-
treated fractions. Healthy
controls without BRCA1
mutations are indicated as WT;
P1 and P2 are positive controls
with exon 13 and exon 22
deletion events, respectively
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mely low compared to the sense probes, and they do not
have known biological meaning. Therefore, the data was
ﬁltered to leave only the data from probes corresponding in
sequence to that of sense BRCA1 mRNA. The normaliza-
tion of the data was performed using a spreadsheet
according to the Manual spreadsheet-based MLPA analysis
instructions (available on the MRC-Holland website:
www.MLPA.com). The threshold values for deletions and
duplications were set to 0.75–1.25, respectively, which are
also used for DNA analysis [13–16].
Results
With the SALSA MLPA P002 kit, strong signals were
obtained for 21 out of 25 probes. These probes contained
more than 85% nucleotides hybridizing to the exon
sequence in the correct orientation. The signals for the
probes with less than 85% matching exonic sequence
(exons 1A, 9 and 19) or in antisense (23) were extremely
weak and often not even detectable by the software. This
also conﬁrms the absence of contaminating genomic DNA
in the RNA samples.
Initially, we have compared the results from puromycin-
treated and non-treated samples (Fig. 1), without DNase I
treatment. The results were not optimal, but it was
observed that the puromycin-treated samples gave better
results than the non-treated. Subsequently, we tested the
effect of two different DNase I treatment options: (1)
DNase I treatment followed by puriﬁcation in a column
system and (2) DNase I treatment kit that allows to remove
the enzyme by precipitation and centrifugation. The results
were considerably improved when the RNAs were cleaned
in a column system (data not shown), i.e. variation in the
signals among individuals was greatly reduced, at least in
two independent experiments.
Six samples from high risk families without a
BRCA1/2 mutation were also analyzed (data not shown)
using the puromycin-treated fractions and RNAs treated
with DNase I and cleaned in a column system. None of
these samples showed an exon skipping event, in the 20
exons tested. However, in an independent third experi-
ment we observed increased interindividual variability in
some exon signals. Many exons had normalized values
outside the 0.75–1.25 thresholds (Fig. 2). This was also
observed in healthy control samples. This hampers the
evaluation of splicing defects as it suggests duplications
or deletions events that would need experimental
follow-up or repetitive MLPA analysis to determine
reproducibility.
Discussion
The MLPA method is widely used in diagnostics, mainly
to test genomic events such as deletions and duplications.
Although there are a few commercial RT-MLPA kits,
these are designed to test the expression of genes associ-
ated with certain biological processes, MRC-Holland
has not developed RT-MLPA kits to test splice events.
Besides the use of the MLPA, or other multiplex
approaches, to test the effect of genetic variants predicted
to affect splicing at the RNA level, it would be useful to
test for BRCA1 and BRCA2 mutation negative patients
with strong breast and/or ovarian cancer history. This
group of patients may carry variants outside the screened
intronic region ﬂanking the exons which could affect
splicing. Since exon skipping is the most common alter-
native splice event [8], developing a test that allows to
screen for exon skipping events would detect the majority
of alternative splice events.
One single study has previously shown that MLPA
could be used to test exon skipping events in RNA tran-
scripts of the DMD gene [9]. Here we report the use of
MLPA kit for the analysis of BRCA1 exon skipping events.
The most optimal results were obtained from puromycin-
treated samples and when RNA was treated with DNase I
and subsequently puriﬁed in a column system. However,
despite efforts to optimize the technique further, we were
not able to get reliable, reproducible results for unequivo-
cal interpretation using the kit BRCA1 P002. This variation
was also observed in healthy control samples, which
showed both deletion and duplication events in one out of
three experiments performed.
MLPA test is a ﬂexible multiplex assay which allows
for up to a total of 50 probes and in principle, it should
be possible to use it for detection of alternative splicing
events other than exon skipping. To be able to test also
for intron retention or insertion of pseudoexons, probes
crossing over exon–exon boundaries should also be
included in the assay. Although mRNA-seq technology
[17] will also allow to test for aberrant splicing events
in patients, MLPA could be a more cost-effective tech-
nique. However, it needs to be optimized further for
routine use.
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